Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[LDL-apheresis therapy, methods and indications].

U Assogba1, F Dairou, G Turpin

  • 1ETS AP-HP (UA), Site Transfusionnel, Service d'Endocrinologie, G.H. Pitié-Salpêtrière.

Presse Medicale (Paris, France : 1983)
|June 15, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Hypercholesterolemia, from screening to treatment: Who, why and how to manage].

La Revue de medecine interne·2020
Same author

Psychological predictors of the combined adoption of physical exercise and dietary change among adults with hypercholesterolemia.

Revue d'epidemiologie et de sante publique·2018
Same author

Lipoprotein-associated phospholipase A₂ activity is increased in patients with definite familial hypercholesterolemia compared with other forms of hypercholesterolemia.

Nutrition, metabolism, and cardiovascular diseases : NMCD·2018
Same author

[Statin treatment must be personalized].

La Revue de medecine interne·2018
Same author

[Familial hypercholesterolemia: A largely underestimated cardiovascular risk].

Annales de cardiologie et d'angeiologie·2017
Same author

Consensus statement on the management of dyslipidaemias in adults.

Annales d'endocrinologie·2017

Homozygote hypercholesterolemia is a severe genetic disorder causing extremely high cholesterol. LDL-apheresis is the most effective treatment to lower cholesterol and prevent cardiovascular complications.

Area of Science:

  • Cardiovascular Medicine
  • Genetics
  • Biochemistry

Context:

  • Homozygote hypercholesterolemia (HoH) is a severe autosomal dominant disorder.
  • Characterized by extremely high serum cholesterol levels (>6 g/l) due to absent LDL-receptors.
  • Leads to high atherogenic potential, with sudden death risk starting at age 10 and near 100% mortality by 20.

Purpose:

  • To highlight the severity of Homozygote hypercholesterolemia.
  • To discuss LDL-apheresis as the primary treatment modality.
  • To compare the availability and financing of LDL-apheresis techniques across European countries.

Summary:

  • HoH is a life-threatening condition with early mortality due to severe hypercholesterolemia.
  • LDL-apheresis is the most effective treatment for lowering LDL cholesterol and preventing cardiovascular events.

Related Experiment Videos

  • Specific LDL-apheresis techniques, though costly, are crucial for pediatric patients, but their development is hindered by financing issues in France.

    • Impact:

    • LDL-apheresis offers a vital therapeutic option for drug-resistant HoH patients.
    • Effective cholesterol lowering can mitigate severe cardiovascular complications and improve long-term prognosis.
    • Addressing financing disparities is crucial for equitable access to advanced treatments like LDL-apheresis, especially for children.